

**NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE**

**Health Technology Evaluation**

**Equality impact assessment – Scoping**

**Talazoparib for treating HER2-negative locally advanced or metastatic breast cancer with germline BRCA1/2-mutations [ID1342]**

The impact on equality has been assessed during this evaluation according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?
No.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?
Not applicable.

3. Has any change to the draft scope been agreed to highlight potential equality issues?
Not applicable.

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the stakeholder list been made?
Not applicable.

**Approved by Associate Director (name):** Henry Edwards

25/10/2022

Health Technology Evaluation: Scoping

Equality impact assessment for the Health Technology Evaluation of talazoparib for treating HER2-negative locally advanced or metastatic breast cancer with germline BRCA1/2-mutations [ID1342]

Issue date: October 2022